Sotirios Tsimikas
Directeur/Bestuurslid bij Oxitope Pharma BV
Oorsprong van het eerstegraads netwerk van Sotirios Tsimikas
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Oxitope Pharma BV
Oxitope Pharma BV Pharmaceuticals: MajorHealth Technology Oxitope Pharma BV is a Dutch pharmaceutical start-up founded in 2020 that focuses on discovering and developing medicine for the treatment of inflammatory and cardiovascular diseases caused by oxidative stress. The company is based in Naarden, Netherlands. The Dutch company takes a different approach to the diagnosis and treatment of these diseases by preventing, halting, or reversing acute and chronic diseases driven by oxidized phospholipids. Oxitope Pharma's goal is to enable people to live long and healthy lives. The CEO is John Montana.
5
| Subsidiary | Pharmaceuticals: Major | 5 |
UC San Diego School of Medicine
4
| College/University | Other Consumer Services | 4 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Sotirios Tsimikas via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
enGene, Inc.
enGene, Inc. BiotechnologyHealth Technology enGene, Inc. develops therapeutic solutions for the treatment of metabolic diseases. It operates as a biotechnology company which develops a mucosal immunotherapy platform for treating several prevalent, chronic diseases including inflammatory bowel disease and diabetes. The firm also develops proprietary, non-integrating biopolymer based nucleotide DNA and siRNA delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. The company was founded in 1999 by Anthony T. Cheung, John C. Brown, Timothy J. Kieffer, and Francis John Gargiulo and is headquartered in Vancouver, Canada. | Biotechnology | Director/Board Member | |
MILESTONE PHARMACEUTICALS INC. | Pharmaceuticals: Major | Director/Board Member | |
Academic Medical Center
Academic Medical Center Hospital/Nursing ManagementHealth Services Academic Medical Center operates a medical center and a medical research facility. It also provides education and training. The company was founded in 1983 and is headquartered in Amsterdam, the Netherlands. | Hospital/Nursing Management | Corporate Officer/Principal | |
The University of Manchester | College/University | Undergraduate Degree | |
Pulmagen Therapeutics (Synergy) Ltd.
Pulmagen Therapeutics (Synergy) Ltd. Miscellaneous Commercial ServicesCommercial Services Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer | |
University of California, Riverside | College/University | Undergraduate Degree | |
University of California San Diego | College/University | Corporate Officer/Principal | |
University of East Anglia | College/University | Doctorate Degree | |
University of Amsterdam | College/University | Corporate Officer/Principal | |
University of Groningen | College/University | Graduate Degree | |
Swiss Federal Institute of Technology | College/University | Doctorate Degree | |
DSM Pharmaceutical Products, Inc.
DSM Pharmaceutical Products, Inc. Chemicals: Major DiversifiedProcess Industries Part of Thermo Fisher Scientific, Inc., DSM Pharmaceutical Products, Inc. is a science-based company that specializes in nutrition, health, and bioscience. The company is based in Parsippany, NJ. The company offers solutions for animal nutrition, human nutrition and care, food and beverage, and materials. DSM's companies cover a range of human and animal health and nutrition businesses. DSM's investor relations team provides key facts and figures, as well as shareholder information, to current and potential shareholders of DSM and to analysts. | Chemicals: Major Diversified | Corporate Officer/Principal | |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Investment Managers | Private Equity Investor Private Equity Investor Director of Finance/CFO Private Equity Investor | |
Biogeneration Management BV
Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden. | Investment Managers | Director of Finance/CFO | |
Glaxo, Inc. | Corporate Officer/Principal | ||
Exosome Diagnostics, Inc.
Exosome Diagnostics, Inc. Medical/Nursing ServicesHealth Services Exosome Diagnostics, Inc. develops and commercializes biofluid-based diagnostics to deliver personalized precision healthcare that improves lives. Its novel exosome-based technology platform can yield comprehensive and dynamic molecular insights to transform how cancer and other serious diseases are detected, diagnosed, treated and monitored. The company was founded by Wayne D. Comper, Harvey J. Barnett and James R. McCullough and is headquartered in Waltham, MA. | Medical/Nursing Services | Director/Board Member | |
Embic Corp.
Embic Corp. Information Technology ServicesTechnology Services Medical Care Corp. specializes in developing technologies for the precise measurement and monitoring of cognitive performance. The company was founded by William R. Shankle and Junko Hara in 1999 and is headquartered in Newport Beach, CA. | Information Technology Services | Corporate Officer/Principal | |
Prexton Therapeutics SA
Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Dutch Atherosclerosis Society | President | ||
Forbion Capital Fund III Coöperatief UA
Forbion Capital Fund III Coöperatief UA Financial ConglomeratesFinance Part of Forbion Capital Partners Management Holding BV, Forbion Capital Fund III Coöperatief UA is a company based in Naarden, Netherlands. The Dutch company provides investment services. | Financial Conglomerates | Director/Board Member | |
Akarna Therapeutics Ltd.
Akarna Therapeutics Ltd. Pharmaceuticals: GenericHealth Technology Akarna Therapeutics Ltd. develops novel small molecule therapeutics. It offers non-bile acid FXR agonist, a therapeutic for the treatment of nonalcoholic steatohepatitis and fatty-liver diseases. The company was founded by Raju Mohan in 2014 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Generic | Director/Board Member | |
Familial Hypercholesterolemia Foundation | Corporate Officer/Principal | ||
Staten Biotechnology BV
Staten Biotechnology BV BiotechnologyHealth Technology Staten Biotechnology BV develops drugs for the treatment of dyslipidemia. The company was founded by Paul da Silva Jardine, Daniel Rader and Alan Tall in 2014 and is headquartered in Nijmegen, the Netherlands. | Biotechnology | Chief Tech/Sci/R&D Officer | |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Biotechnology | Director/Board Member | |
Metrion Biosciences Ltd.
Metrion Biosciences Ltd. BiotechnologyHealth Technology Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016. | Biotechnology | Director/Board Member | |
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member | |
Tau Ventures LLC
Tau Ventures LLC Investment ManagersFinance Tau Ventures LLC (Tau Ventures) is a venture capital firm founded in 2018 by Amit Garg and Sanjay K. Rao. The firm is headquartered in Palo Alto, California. | Investment Managers | Consultant / Advisor | |
The Docs, Inc.
The Docs, Inc. The Docs, Inc. plans to provide a clinic that keeps diabetes prevention and treatment in mind while integrating proactive screenings of the associated co-morbidities. The company was founded by Mark A. Cole on April 16, 2017 and is headquartered in Las Vegas, NV. | Chief Tech/Sci/R&D Officer | ||
NewAmsterdam Pharma Holding BV
NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Biotechnology | Founder | |
VectorY BV
VectorY BV Miscellaneous Commercial ServicesCommercial Services VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
Rectify Pharmaceuticals LLC
Rectify Pharmaceuticals LLC Miscellaneous Commercial ServicesCommercial Services Rectify Pharmaceuticals LLC is a biotech company that is developing positive functional modulators (PFMs) to address the underlying cause of serious ABC transporter-mediated diseases. The company is based in Cambridge, MA and was founded by Jonathan Moore. The company's team includes Xiaobing Li as Chief Development Officer, Robert Hughes as Executive Vice President of Drug Discovery and Preclinical Development, and Leif-Ann Tuohey as Senior Vice President and Head of Business Development. The company has received $100 million in Series A financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund. The CEO is Rajesh Devraj, who is also a venture partner at Atlas Venture. | Miscellaneous Commercial Services | Director/Board Member | |
FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Vascular Research Network B V | Chief Executive Officer | ||
St. Georges University School of Medicine
St. Georges University School of Medicine Other Consumer ServicesConsumer Services St. Georges University School of Medicine. The company is headquartered in Grenada. | College/University | Graduate Degree | |
NewAmsterdam Pharma BV
NewAmsterdam Pharma BV Pharmaceuticals: MajorHealth Technology NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands. | Pharmaceuticals: Major | Director/Board Member |
Statistieken
Internationaal
Nederland | 14 |
Verenigde Staten | 11 |
Verenigd Koninkrijk | 7 |
Canada | 5 |
Duitsland | 3 |
Sectoraal
Health Technology | 14 |
Consumer Services | 9 |
Commercial Services | 6 |
Finance | 5 |
Health Services | 3 |
Operationeel
Director/Board Member | 22 |
Corporate Officer/Principal | 15 |
Chief Tech/Sci/R&D Officer | 5 |
Private Equity Investor | 4 |
Doctorate Degree | 3 |
Sterkste connecties
Insiders | |
---|---|
Marco Boorsma | 15 |
John Kastelein | 11 |
John Montana | 10 |
Asheesh K. Dewan | 5 |
Vincent van Houten | 4 |
Joseph L. Witztum | 2 |
Michael Rafii | 2 |
Ralph Greenspan | 1 |
Marek Dobke | 1 |
- Beurs
- Insiders
- Sotirios Tsimikas
- Bedrijfsconnecties